Author
Listed:
- Ahmet Ucar
(Max Planck Institute of Biophysical Chemistry
Cellular Senescence Group, Cell and Tumor Biology Program, German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance)
- Shashi K. Gupta
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Jan Fiedler
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Erdem Erikci
(Max Planck Institute of Biophysical Chemistry)
- Michal Kardasinski
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Sandor Batkai
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Seema Dangwal
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Regalla Kumarswamy
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Claudia Bang
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Angelika Holzmann
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Janet Remke
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School)
- Massimiliano Caprio
(Centre for Clinical and Basic Research, IRCCS San Raffaele)
- Claudia Jentzsch
(Institut für Pharmakologie und Toxikologie, Technische Universität München)
- Stefan Engelhardt
(Institut für Pharmakologie und Toxikologie, Technische Universität München
Munich Heart Alliance)
- Sabine Geisendorf
(Max Planck Institute of Biophysical Chemistry)
- Carolina Glas
(Cellular Senescence Group, Cell and Tumor Biology Program, German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance)
- Thomas G. Hofmann
(Cellular Senescence Group, Cell and Tumor Biology Program, German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance)
- Michelle Nessling
(Core Facility Electron Microscopy, German Cancer Research Center (DKFZ))
- Karsten Richter
(Core Facility Electron Microscopy, German Cancer Research Center (DKFZ))
- Mario Schiffer
(Hannover Medical School
Mount Desert Island Biological Laboratories)
- Lucie Carrier
(Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf)
- L. Christian Napp
(Hannover Medical School)
- Johann Bauersachs
(Hannover Medical School)
- Kamal Chowdhury
(Max Planck Institute of Biophysical Chemistry)
- Thomas Thum
(Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
Centre for Clinical and Basic Research, IRCCS San Raffaele)
Abstract
Pathological growth of cardiomyocytes (hypertrophy) is a major determinant for the development of heart failure, one of the leading medical causes of mortality worldwide. Here we show that the microRNA (miRNA)-212/132 family regulates cardiac hypertrophy and autophagy in cardiomyocytes. Hypertrophic stimuli upregulate cardiomyocyte expression of miR-212 and miR-132, which are both necessary and sufficient to drive the hypertrophic growth of cardiomyocytes. MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice. Both miR-212 and miR-132 directly target the anti-hypertrophic and pro-autophagic FoxO3 transcription factor and overexpression of these miRNAs leads to hyperactivation of pro-hypertrophic calcineurin/NFAT signalling and an impaired autophagic response upon starvation. Pharmacological inhibition of miR-132 by antagomir injection rescues cardiac hypertrophy and heart failure in mice, offering a possible therapeutic approach for cardiac failure.
Suggested Citation
Ahmet Ucar & Shashi K. Gupta & Jan Fiedler & Erdem Erikci & Michal Kardasinski & Sandor Batkai & Seema Dangwal & Regalla Kumarswamy & Claudia Bang & Angelika Holzmann & Janet Remke & Massimiliano Capr, 2012.
"The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy,"
Nature Communications, Nature, vol. 3(1), pages 1-11, January.
Handle:
RePEc:nat:natcom:v:3:y:2012:i:1:d:10.1038_ncomms2090
DOI: 10.1038/ncomms2090
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:3:y:2012:i:1:d:10.1038_ncomms2090. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.